ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fluticasone

Also written as “Fluticasone Propionate”, “Fluticasone propionate” and “Fluticasone Propionate/Formoterol Fumarate”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Rhinitis, Allergic, Perennial, led by 24 companies.

Drug pageFluticasone: every studyMany companies study it; this page follows only the 150 they lead. All 340 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 1, 2005150 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only580 open or runningphase 4since Feb 1, 2005Feb 1, 2005none ahead
Respirent Pharmaceuticalsits history only182 open or runningphase 3since Sep 17, 2018Sep 17, 2018none ahead
Teva Pharmaceutical Industriesits history only140 open or runningphase 4since Dec 11, 2020Nov 22, 2011none ahead
Viatrisits history only130 open or runningphase 4since Dec 16, 2016Nov 21, 2006none ahead
Optinose USits history only101 open or runningphase 3since Jun 13, 2012Jun 13, 2012Mar 31, 2028phase 3 · NCT06850805
Mundipharmaits history only60 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
SkyePharmaits history only50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only31 open or runningphase 3since Sep 14, 2010Sep 14, 2010Aug 2028phase 3 · NCT06234345
Merckits history only30 open or runningphase 2since Oct 5, 2006Oct 5, 2006none ahead
Hikma Pharmaceuticalsits history only20 open or runningno phasesince Jan 5, 2016Jan 5, 2016none ahead

Also a collaborator on its studies: Paratek Pharmaceuticals, Becro, Prolytic, Dynamic Solutions, Parexel, Vectura and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Feb 15, 2013.

  1. Dec 7, 2020Phase 3 study in AsthmaRespirent Pharmaceuticals · NCT04665895 · 451 enrolled · Greece
  2. Dec 11, 2020Phase 4 study in AsthmaTeva Pharmaceutical Industries · NCT04677959 · 427 enrolled · United States
  3. Dec 15, 2020Phase 2 study in BlepharitisNicox Ophthalmics · NCT04675242 · 224 enrolled · United States
  4. Feb 8, 2021Phase 1 study in AsthmaRespirent Pharmaceuticals · NCT04746040 · 50 enrolled · Greece
  5. Aug 19, 2021Phase 1 study in AsthmaRespirent Pharmaceuticals · NCT05021887 · 50 enrolled · Greece
  6. Oct 8, 2021Phase 1 study in AsthmaRespirent Pharmaceuticals · NCT05085587 · 18 enrolled · Greece
  7. May 2, 2022Glenmark Pharmaceuticals Ltd. India’s first study: phase 3 study in AsthmaNew to Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals Ltd. India · NCT05363202 · 790 enrolled · India
  8. May 25, 2022Phase 1 study in AsthmaRespirent Pharmaceuticals · NCT05397834 · 36 enrolled · Greece
  9. Dec 15, 2022Phase 3 study in AsthmaRespirent Pharmaceuticals · NCT05664061 · 451 enrolled · Greece
  10. Jan 10, 2023Phase 1 study in BioequivalenceRespirent Pharmaceuticals · NCT05697003 · 34 enrolled · Greece
  11. Aug 1, 20232 phase 1 studies in BioequivalenceRespirent Pharmaceuticals · NCT05982990, NCT06025214
  12. Jan 3, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveEurofarma Laboratorios · NCT06234345 · 1,252 planned · Brazil
  13. Feb 14, 2025Phase 3 study in Chronic Rhinosinusitis Without Nasal PolypsOptinose US · NCT06850805 · 84 planned · United States
  14. Aug 31, 2026HALEON’s first study: phase 4 study in Rhinitis, Allergic, PerennialNew to HALEONHALEON · NCT07817134 · 16 planned · Canada

Ahead

  1. Dec 2026Primary completion: phase 4 study in Rhinitis, Allergic, PerennialHALEON · NCT07817134
  2. Mar 31, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis Without Nasal PolypsOptinose US · NCT06850805
  3. Aug 2028Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveEurofarma Laboratorios · NCT06234345

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The newest 60 of 150 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07817134Rhinitis, Allergic, Perennial · Canada4Not yet recruitingHALEONDec 202616
NCT06850805Chronic Rhinosinusitis Without Nasal Polyps · United States3RecruitingOptinose USMar 31, 202884
NCT06234345Pulmonary Disease, Chronic Obstructive · Brazil3Not yet recruitingEurofarma LaboratoriosAug 20281,252
NCT06025214Bioequivalence · Greece1RecruitingRespirent PharmaceuticalsSep 22, 202334
NCT05982990Bioequivalence · Greece1Active, not recruitingRespirent PharmaceuticalsSep 1, 202334
NCT05697003Bioequivalence · Greece1UNKNOWNRespirent PharmaceuticalsMar 31, 202334
NCT05664061Asthma · Greece3UNKNOWNRespirent PharmaceuticalsJul 31, 2023451
NCT05397834Asthma · Greece1UNKNOWNRespirent PharmaceuticalsJun 21, 202236
NCT05363202Asthma · India3UNKNOWNGlenmark Pharmaceuticals Ltd. IndiaMay 30, 2024790
NCT05085587Asthma · Greece1UNKNOWNRespirent PharmaceuticalsOct 25, 202118
NCT05021887Asthma · Greece1UNKNOWNRespirent PharmaceuticalsSep 30, 202150
NCT04746040Asthma · Greece1UNKNOWNRespirent PharmaceuticalsFeb 25, 202150
NCT04675242Blepharitis · United States2CompletedNicox OphthalmicsJun 16, 2021224
NCT04677959Asthma · United States4CompletedTeva Pharmaceutical IndustriesMar 4, 2022427
NCT04665895Asthma · Greece3CompletedRespirent PharmaceuticalsAug 13, 2021451
NCT04564456Bioequivalence · Greece1CompletedRespirent PharmaceuticalsOct 31, 202034
NCT04546256Bioequivalence · Greece1CompletedRespirent PharmaceuticalsSep 25, 202014
NCT04466176Bioequivalence · Greece1CompletedRespirent PharmaceuticalsAug 4, 202034
NCT04462822Bioequivalence · Greece1CompletedRespirent PharmaceuticalsSep 9, 202014
NCT04332978Rhinitis, Allergic, Perennial3CompletedLibbs Farmacêutica LTDAApr 1, 2020566
NCT04271839Persistent Asthma4WithdrawnMundipharmaMay 20210
NCT03975166Bioequivalence · Greece1CompletedRespirent PharmaceuticalsJun 25, 201934
NCT03960580Chronic Rhinosinusitis · United States, Australia, Bulgaria and more3CompletedOptinose USMay 4, 2022223
NCT03926026Blepharitis · United States2CompletedNicox OphthalmicsOct 21, 201936
NCT03894280Bioequivalence · Greece1CompletedRespirent PharmaceuticalsApr 9, 201936
NCT03820180Bioequivalence · Greece1CompletedRespirent PharmaceuticalsFeb 12, 201934
NCT03781804Chronic Rhinosinusitis · United States, Bulgaria, Canada and more3CompletedOptinose USJan 19, 2022332
NCT03756883Asthma · United States3CompletedTeva Pharmaceutical IndustriesOct 26, 2019999
NCT03751202Bioequivalence · Greece1CompletedRespirent PharmaceuticalsDec 11, 201834
NCT03747458Bilateral Nasal Polyposis · United States, Argentina3CompletedOptinose USMar 31, 202640
NCT03676413Asthma · Greece3CompletedRespirent PharmaceuticalsAug 2, 2019451
NCT03591068Nasal Polyps · United States3CompletedOptinose USFeb 22, 201911
NCT03535870Asthma · United States–CompletedHikma PharmaceuticalsSep 10, 20191,556
NCT03394989Asthma · United States3CompletedCiplaDec 3, 20191,366
NCT03387241Asthma · China3UNKNOWNMundipharmaDec 30, 2019330
NCT03004131Rhinitis, Allergic, Seasonal · Canada4CompletedViatrisMar 29, 201782
NCT02980133Asthma · United States, Georgia, Hungary and more3CompletedTeva Pharmaceutical IndustriesApr 7, 2019841
NCT02730351Asthma · United States, Canada4CompletedGlaxoSmithKlineFeb 3, 201775
NCT02680561Asthma · United States1CompletedTeva Pharmaceutical IndustriesJun 201620
NCT02693769ACOS (Fixed Airflow Obstruction and Elevated Eosinophils) · Slovakia3TerminatedMundipharmaOct 20162
NCT02649478Asthma · United States–CompletedHikma PharmaceuticalsNov 20151,430
NCT02496715Asthma3WithdrawnTeva Pharmaceutical IndustriesOct 20160
NCT02491970Asthma4TerminatedMundipharmaApr 6, 201715
NCT02466503Asthma · Taiwan1CompletedIntech BiopharmSep 201445
NCT02466347Asthma · Taiwan1CompletedIntech BiopharmAug 201445
NCT02437604Asthma · United States1CompletedTeva Pharmaceutical IndustriesJul 201543
NCT02301975Asthma · United States, Argentina, Brazil and more3CompletedGlaxoSmithKlineNov 1, 20161,526
NCT02266927Mild to Moderate Asthma · Ireland1CompletedOptinose USMar 201528
NCT02249663Rhinitis, Allergic, Seasonal · United States3UNKNOWNTeva Pharmaceutical IndustriesFeb 20151,535
NCT02246920Rhinitis, Allergic, Seasonal · United States3TerminatedTeva Pharmaceutical IndustriesJul 14, 20141,474
NCT02232087Healthy · United Kingdom1CompletedKindeva Drug DeliveryOct 201452
NCT02215122Asthma · United States1CompletedViatrisNov 201340
NCT02175771Persistent Asthma · United States3CompletedTeva Pharmaceutical IndustriesJul 2015758
NCT02141854Asthma · United States, Canada, Czechia and more3CompletedTeva Pharmaceutical IndustriesSep 2015882
NCT02139644Asthma · United States, Canada, Czechia and more3CompletedTeva Pharmaceutical IndustriesSep 2015787
NCT02094937Asthma · Japan3CompletedGlaxoSmithKlineAug 28, 2015430
NCT01915823Rhinitis, Allergic, Seasonal · United States3CompletedViatrisFeb 2014348
NCT01915914Skin Diseases · China4CompletedGlaxoSmithKlineFeb 15, 2015107
NCT01817790Rhinitis, Allergic · United States3CompletedGlaxoSmithKlineFeb 2013626
NCT01794741Rhinitis, Allergic · United States3CompletedViatrisNov 2013405

How it is read

Names in the registry

  • “Fluticasone Propionate”, 17 entries
  • “Fluticasone propionate”, 13 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “fluticasone propionate”, 7 entries
  • “fluticasone propionate/salmeterol”, 7 entries

Codes read as this program: NCX4251, FP100.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.